Key result
DOAC reversal agents achieve ~79% effective hemostasis in severe bleeding, but failure sharply increases mortality.
Why the study?
Major bleeding occurs in 2% to 3.5% of DOAC-treated patients annually, often requiring reversal agents, but clinical outcomes associated with their use needed investigation.
Do reversal agents improve hemostatic efficacy and clinical outcomes in patients with severe DOAC-related bleeding?
Meta-Analysis (n=4,735)
Do reversal agents improve hemostatic efficacy and clinical outcomes in patients with severe DOAC-related bleeding?
In patients with severe DOAC-related bleeding, reversal agents achieve high rates of effective hemostasis, but mortality remains significant and andexanet is associated with higher thromboembolism rates.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“This study is a welcome overview of the available evidence of who is getting which reversal agents and related outcomes.”
“Not achieving effective hemostasis was strongly correlated with a more than 3-fold increase in the risk of death. Therefore, in the event of insufficient hemostatic response, additional attempts and/or combination with other treatment modalities aimed at achieving effective hemostasis should be considered.”
Effective hemostasis with DOAC reversal was associated with lower mortality; leaves open agent-specific safety and need for randomized comparisons.
BACKGROUND: Direct oral anticoagulants (DOACs) have shown a positive benefit-risk balance in both clinical trials and real-world data, but approximately 2% to 3.5% of patients experience major bleeding annually. Many of these patients require hospitalization, and the administration of reversal agents may be required to control bleeding. OBJECTIVES: The aim of this study was to investigate clinical outcomes associated with the use of 4-factor prothrombin complex concentrates, idarucizumab, or andexanet for reversal of severe DOAC-associated bleeding. METHODS: The investigators systematically searched for studies of reversal agents for the treatment of severe bleeding associated with DOAC. Mortality rates, thromboembolic events, and hemostatic efficacy were meta-analyzed using a random effects model. RESULTS: The investigators evaluated 60 studies in 4,735 patients with severe DOAC-related bleeding who were treated with 4-factor prothrombin complex concentrates (n = 2,688), idarucizumab (n = 1,111), or andexanet (n = 936). The mortality rate was 17.7% (95% confidence interval [CI]: 15.1% to 20.4%), and it was higher in patients with intracranial bleedings (20.2%) than in patients with extracranial hemorrhages (15.4%). The thromboembolism rate was 4.6% (95% CI: 3.3% to 6.0%), being particularly high with andexanet (10.7%; 95% CI: 6.5% to 15.7%). The effective hemostasis rate was 78.5% (95% CI: 75.1% to 81.8%) and was similar regardless of the reversal agent considered. The rebleeding rate was 13.2% (95% CI: 5.5% to 23.1%) and 78% of rebleeds occurred after resumption of anticoagulation. The risk of death was markedly and significantly associated with failure to achieve effective hemostasis (relative risk: 3.63; 95% CI: 2.56 to 5.16). The results were robust regardless of the type of study or the hemostatic scale used. CONCLUSIONS: The risk of death after severe DOAC-related bleeding remains significant despite a high rate of effective hemostasis with reversal agents. Failure to achieve effective hemostasis strongly correlated with a fatal outcome. Thromboembolism rates are particularly high with andexanet. Comparative clinical trials are needed.
No takes yet. Share an insight, caveat, or question.
Gómez‐Outes et al. (2021) conducted a meta-analysis in Severe DOAC-related bleeding (n=4,735). Reversal agents (4-factor prothrombin complex concentrates, idarucizumab, or andexanet) was evaluated on Mortality rate (95% CI 15.1 to 20.4). In patients with severe DOAC-related bleeding, reversal agents achieved 78.5% effective hemostasis, but mortality was 17.7%, and failure to achieve hemostasis increased death risk.
Synapse has enriched 10 related papers. Consider them for comparative context: